RESUMO
The interleukin-15 is a unique proinflammatory cytokine associated with immune response regulation and the growth, survival, and biological behavior of leukemic cells. This study assesses the effect of both types of acute malignancies, lymphoid and myeloid, on the interleukin-15 serum levels for Acute Lymphoid Leukemia and Acute Myeloid Leukemia patients. The interleukin-15 serum levels were measured for 21 acute lymphoid leukemia patients and 21 acute myeloid leukemia patients compared to healthy people (24) as a control group using the ELISA Peprotech Company (USA), a protocol kit. The research data explain a significant decrease in interleukin-15 serum level for acute lymphoid leukemia (ALL) patients (99 pg/ml)compared with the healthy group (126 pg/ml) at level (P value=0.009), while the acute myeloid leukemia (AML) (141 pg/ml) patients recorded a nonsignificant increase in IL-15 serum level from the healthy group at (P>0.05). The data outcome clarified an important effect of acute lymphoid leukemia in reduced proinflammatory interleukin-15 serum level due to impairment in T and B lymphocyte production, which is correlated with immunosuppression response toward leukemia, while acute myeloid leukemia non-significantly increases the interleukin-15 serum level.
